E. Gouzoulis-Mayfrank

Publications214
h-index37
Citations3,863
Highly Influential Citations248
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Daumann
  • 69 Publications, 2,577 Citations
  • A. Parrott
  • 213 Publications, 8,511 Citations
  • M. Geyer
  • 598 Publications, 41,258 Citations
  • G. Ricaurte
  • 200 Publications, 15,296 Citations
  • Publications
  • Influence
The role of cannabis in cognitive functioning of patients with schizophrenia
RationaleCognitive deficits are commonly found both in patients with schizophrenia (SCH) and in people with cannabis use disorders (CUD). Surprisingly, some small recent studies reported better… Expand
  • 92
  • 15
  • PDF
Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users
Previous studies have consistently shown impairments of memory and learning in regular users of the neurotoxic drug ecstasy (3,4-methylenedioxymethamphetamine [MDMA]). In addition, deficits in… Expand
  • 145
  • 13
Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
INTRODUCTION Pharmacological challenges with hallucinogens are used as models for psychosis in experimental research. The state induced by glutamate antagonists such as phencyclidine (PCP) is often… Expand
  • 141
  • 11
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind…
Abstract The aim of this study was to contribute to the characterization of the entactogen (ecstasy) substance group. The psychopathological, neuroendocrine and autonomic effects of common… Expand
  • 125
  • 11
  • PDF
Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG
The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4-methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2–0.4 mg/kg)… Expand
  • 128
  • 10
  • PDF
High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users
Neurotoxic damage of central serotonergic systems has been demonstrated in numerous animal studies after exposure to methylenedioxyamphetamines (ecstasy). A high intensity dependence of auditory… Expand
  • 101
  • 8
  • PDF
Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal…
Rationale3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) has become a widely used recreational drug among young people. This is of great concern, since MDMA is neurotoxic in animal studies and its… Expand
  • 93
  • 8
  • PDF
Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study.
The popular recreational drug ecstasy (3,4-methylenedioxymethamphetamine=MDMA and related congeners) is neurotoxic upon central serotonergic systems in animal studies. So far, the most convincing… Expand
  • 62
  • 8
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
OBJECTIVES Ecstasy (3,4-methylenedioxymethamphetamine (MDMA) and related congerers: MDA, MDEA) is the name given to a group of popular recreational drugs. Animal data raise concern about neurotoxic… Expand
  • 200
  • 7
  • PDF
Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
RationaleMany studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic… Expand
  • 119
  • 7
  • PDF